M. Cullen

发表

Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial.

S. Fosså, D. Dearnaley, A. Horwich, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

CLINICAL STUDIES

M. Williams, S. Fosså, P. Gerszten, 2004 .

Adjuvant and neo-adjuvant chemotherapy in non-small cell carcinoma.

M. Cullen, M. H. Cullen, 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours

M. Williams, S. Fosså, A. Horwich, 1999, British Journal of Cancer.

Management of patients with non-seminomatous germ cell tumours stage I.

A. Horwich, M. Ro̸rth, B. Roth, 1990, Progress in clinical and biological research.

Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: a Randomized Medical Research Council/European Organization for Research and Treatment of Cancer study.

R Sylvester, L Collette, L. Collette, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United Kingdom.

L. Collette, S. Fosså, S. Kaye, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Optimal planning target volume for stage I testicular seminoma: A Medical Research Council randomized trial. Medical Research Council Testicular Tumor Working Group.

S. Fosså, A. Horwich, J. Owen, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Radiotherapy after chemotherapy for metastatic seminoma--a diminishing role. MRC Testicular Tumour Working Party.

A. Horwich, G. Rustin, S. Kaye, 1997, European journal of cancer.

A Medical Research Council randomized trial of single agent carboplatin versus etoposide and cisplatin for advanced metastatic seminoma

S. Fosså, D. Dearnaley, A. Horwich, 2000, British Journal of Cancer.

A phase II trial of TIP (paclitaxel, ifosfamide and cisplatin) given as second-line (post-BEP) salvage chemotherapy for patients with metastatic germ cell cancer: a medical research council trial

R. Huddart, G. Rustin, G. Mead, 2005, British Journal of Cancer.

Primum non nocere: do we harm stage I testicular cancer patients less by applying adjuvant chemotherapy than by failing to present this option?

J. Oldenburg, M. Cullen, T. Tandstad, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis: a Medical Research Council report.

M. Williams, S. Fosså, A. Horwich, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

D. Dearnaley, A. Horwich, R. Sylvester, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic factors for patients with advanced seminoma treated with platinum-based chemotherapy.

S. Fosså, A. Horwich, S. Kaye, 1997, European journal of cancer.

Consolidation radiotherapy is associated with improved outcomes after chemotherapy for advanced Hodgkin lymphoma: analysis of results from the UKLG LY09 Trial (ISRCTN97144519)

Sydes, J. Radford, S. Stenning, 2008 .

Adjuvant bleomycin, vincristine and cisplatin (BOP) for high-risk stage I non-seminomatous germ cell tumours: a prospective trial (MRC TE17)

M. Williams, S. Fosså, D. Dearnaley, 2005, British Journal of Cancer.

Adjuvant therapy for stage I testicular cancer.

N. James, M. Cullen, 1996, Cancer treatment reviews.

Short course adjuvant chemotherapy in high risk stage I non-seminomatous germ cell tumours of the testis - preliminary report of an MRC study

M. Cullen, S. Stenning, S. Fosså, 1992 .

Medical Research Council prospective study of surveillance for stage I testicular teratoma. Medical Research Council Testicular Tumors Working Party.

A. Horwich, S. Kaye, S. Stenning, 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

ADVANCES IN THE MANAGEMENT OF CYTOTOXIC DRUG‐INDUCED NAUSEA AND VOMITING

M. Cullen, A. J. Freeman, 1991, Journal of clinical pharmacy and therapeutics.

ARE WE MAKING PROGRESS IN THE DRUG TREATMENT OF LUNG CANCER?

M. Cullen, M. Cullen, G. Benfield, 1986, Journal of clinical and hospital pharmacy.

Neoplastic angioendotheliomatosis: a treatable "vascular dementia" occurring in an immunosuppressed transplant patient.

M. Cullen, A. Williams, M. Heafield, 1993, Clinical neuropathology.

Initial dose intensity has limited impact on the outcome of ABVD chemotherapy for advanced Hodgkin lymphoma (HL): data from UKLG LY09 (ISRCTN97144519).

M. Sydes, J. Radford, P. Johnson, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

Personalizing, not patronizing: the case for patient autonomy by unbiased presentation of management options in stage I testicular cancer.

S. Fosså, A. Horwich, J. Aparicio, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Adjuvant bleomycin, vincristine and cisplatin (BOP) for high risk clinical stage I (HRCS 1) non-seminomatous germ cell tumours (NSGCT) - a Medical Research Council (MRC) pilot study.

M. Williams, S. Fosså, D. Dearnaley, 1998 .

Short Course Adjuvant Chemotherapy in High Risk Stage I Non-Seminomatous Germ Cell Tumours of the Testis (NSGCTT): An MRC Study Report

M. Cullen, 1994 .

Randomised comparison of ABVD with two multi-drug regimens (MDRs) in the treatment of advanced Hodgkin lymphoma (HL): Initial results of the UKLG LY09 study (ISRCTN 97144519).

Sydes, J. Radford, Paul D. Smith, 2003 .

Primary chemotherapy after orchidectomy for stage I and II nonseminoma.

A. Horwich, M. Cullen, S. Stenning, 1998, Seminars in oncology.

Long-term toxicity of chemotherapy for testicular cancer--the cost of cure.

R. Grundy, M. Cullen, M. Cullen, 1990, British Journal of Cancer.

A phase II trial of TIP (paclitaxel, ifosfamide and cisplatin) given as second-line (post-BEP) salvage chemotherapy for patients with metastatic germ cell cancer: a medical research council trial

R. Huddart, G. Rustin, G. Mead, 2005, British Journal of Cancer.

Long-term toxicity of chemotherapy for testicular cancer--the cost of cure.

R. Grundy, M. Cullen, P. Cathébras, 1990, British Journal of Cancer.